Phase 1b/2a Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE) In Cystic Fibrosis Patients With Chronic Infections Due To Pseudomonas Aeruginosa.

Trial Profile

Phase 1b/2a Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE) In Cystic Fibrosis Patients With Chronic Infections Due To Pseudomonas Aeruginosa.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Amikacin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Adverse reactions
  • Sponsors Insmed
  • Most Recent Events

    • 04 May 2012 Actual end date (1 Feb 2010) added as reported by ClinicalTrials.gov.
    • 04 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jun 2011 Results presented at the 34th European Cystic Fibrosis Conference, according to a Insmed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top